{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:18Z","timestamp":1787026938674,"version":"build-2736575974"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00028","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T23:23:27Z","timestamp":1518737007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer"],"prefix":"10.3389","volume":"8","author":[{"given":"Johnny R.","family":"Ramroop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1074\/jbc.M310206200","article-title":"Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland","volume":"279","author":"Nantermet","year":"2004","journal-title":"J Biol Chem"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1200\/JCO.2012.43.3441","article-title":"Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion","volume":"30","author":"Basch","year":"2012","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3816\/CGC.2003.n.011","article-title":"Ten-year survival in patients with metastatic prostate cancer","volume":"2","author":"Tangen","year":"2003","journal-title":"Clin Prostate Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","volume":"90","author":"O\u2019Donnell","year":"2004","journal-title":"Br J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e13500","DOI":"10.1371\/journal.pone.0013500","article-title":"Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models","volume":"5","author":"Marques","year":"2010","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","article-title":"A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth","volume":"69","author":"Guo","year":"2009","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"474.e","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"key":"B16","first-page":"831","article-title":"Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer","volume":"28","author":"Aparicio","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11912-017-0593-6","article-title":"Emerging variants of castration-resistant prostate cancer","volume":"19","author":"Vlachostergios","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"key":"B20","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","article-title":"Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat Genet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3892\/ijo.2014.2601","article-title":"Targeting the PI3K\/Akt pathway in prostate cancer: challenges and opportunities (review)","volume":"45","author":"Toren","year":"2014","journal-title":"Int J Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ccell.2017.02.004","article-title":"SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K\/mTOR and AR signaling","volume":"31","author":"Blattner","year":"2017","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e60408","DOI":"10.1371\/journal.pone.0060408","article-title":"PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells","volume":"8","author":"Chatterjee","year":"2013","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3892\/ijo_00000434","article-title":"Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells","volume":"35","author":"Kajanne","year":"2009","journal-title":"Int J Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1080\/14737140.2016.1243474","article-title":"PARP inhibitors and stratified treatment of prostate cancer","volume":"16","author":"Lavery","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1590\/S1677-55382010000500008","article-title":"The use of immunohistochemistry for diagnosis of prostate cancer","volume":"36","author":"Leite","year":"2010","journal-title":"Int Braz J Urol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S307","DOI":"10.4103\/0975-7406.100281","article-title":"Applications of immunohistochemistry","volume":"4","author":"Duraiyan","year":"2012","journal-title":"J Pharm Bioallied Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/pmic.200300598","article-title":"Signal pathway profiling of prostate cancer using reverse phase protein arrays","volume":"3","author":"Grubb","year":"2003","journal-title":"Proteomics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10549-015-3654-2","article-title":"Clinical utility of reverse phase protein array for molecular classification of breast cancer","volume":"155","author":"Negm","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B38","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nprot.2016.057","article-title":"Six alternative proteases for mass spectrometry-based proteomics beyond trypsin","volume":"11","author":"Giansanti","year":"2016","journal-title":"Nat Protoc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"E127","DOI":"10.1038\/ncb0502-e127","article-title":"The origins of protein phosphorylation","volume":"4","author":"Cohen","year":"2002","journal-title":"Nat Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.celrep.2014.07.036","article-title":"Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser\/Thr-based signaling","volume":"8","author":"Sharma","year":"2014","journal-title":"Cell Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2006.09.026","article-title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks","volume":"127","author":"Olsen","year":"2006","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1074\/mcp.M200025-MCP200","article-title":"Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics","volume":"1","author":"Ong","year":"2002","journal-title":"Mol Cell Proteomics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nbt1046","article-title":"Immunoaffinity profiling of tyrosine phosphorylation in cancer cells","volume":"23","author":"Rush","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1021\/acs.jproteome.5b00981","article-title":"Accounting for the multiple natures of missing values in label-free quantitative proteomics data sets to compare imputation strategies","volume":"15","author":"Lazar","year":"2016","journal-title":"J Proteome Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"Cox","year":"2008","journal-title":"Nat Biotechnol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","article-title":"Skyline: an open source document editor for creating and analyzing targeted proteomics experiments","volume":"26","author":"MacLean","year":"2010","journal-title":"Bioinformatics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"rs6","DOI":"10.1126\/scisignal.2003573","article-title":"Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells","volume":"6","author":"Casado","year":"2013","journal-title":"Sci Signal"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cell.2016.07.007","article-title":"Phosphoproteome integration reveals patient-specific networks in prostate cancer","volume":"166","author":"Drake","year":"2016","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/pmic.201400449","article-title":"Visualization of LC-MS\/MS proteomics data in MaxQuant","volume":"15","author":"Tyanova","year":"2015","journal-title":"Proteomics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mas.21540","article-title":"The Skyline ecosystem: informatics for quantitative mass spectrometry proteomics","author":"Pino","year":"2017","journal-title":"Mass Spectrom Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1073\/pnas.1120985109","article-title":"Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression","volume":"109","author":"Drake","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B52","doi-asserted-by":"publisher","first-page":"E4762","DOI":"10.1073\/pnas.1319948110","article-title":"Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets","volume":"110","author":"Drake","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1093\/bioinformatics\/btt471","article-title":"Discovering causal pathways linking genomic events to transcriptional states using tied diffusion through interacting events (TieDIE)","volume":"29","author":"Paull","year":"2013","journal-title":"Bioinformatics"},{"key":"B54","doi-asserted-by":"publisher","first-page":"E172","DOI":"10.1073\/pnas.1521674112","article-title":"Functional screen identifies kinases driving prostate cancer visceral and bone metastasis","volume":"113","author":"Faltermeier","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B55","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/1535-7163.MCT-13-0225-T","article-title":"Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer","volume":"13","author":"Lee","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/onc.2014.206","article-title":"In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth","volume":"34","author":"Jiang","year":"2015","journal-title":"Oncogene"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/pmic.201500365","article-title":"Phosphoproteome analysis demonstrates the potential role of THRAP3 phosphorylation in androgen-independent prostate cancer cell growth","volume":"16","author":"Ino","year":"2016","journal-title":"Proteomics"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/elps.200600782","article-title":"Toward a global characterization of the phosphoproteome in prostate cancer cells: identification of phosphoproteins in the LNCaP cell line","volume":"28","author":"Giorgianni","year":"2007","journal-title":"Electrophoresis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1021\/pr900338q","article-title":"Characterization of the phosphoproteome in LNCaP prostate cancer cells by in-gel isoelectric focusing and tandem mass spectrometry","volume":"9","author":"Chen","year":"2010","journal-title":"J Proteome Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1039\/c2mb25151e","article-title":"Large scale phosphoproteome analysis of LNCaP human prostate cancer cells","volume":"8","author":"Myung","year":"2012","journal-title":"Mol Biosyst"},{"key":"B61","doi-asserted-by":"publisher","first-page":"541","DOI":"10.5858\/arpa.2012-0145-OA","article-title":"Use of immunohistochemistry in routine workup of prostate needle biopsies: a tertiary academic institution experience","volume":"137","author":"Watson","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1158\/1541-7786.MCR-14-0569","article-title":"Measuring PI3K activation: clinicopathologic, immunohistochemical, and RNA expression analysis in prostate cancer","volume":"13","author":"Martin","year":"2015","journal-title":"Mol Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13000-016-0511-5","article-title":"Quantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor beta2 immunohistochemistry in prostate cancer","volume":"11","author":"Rizzardi","year":"2016","journal-title":"Diagn Pathol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/pmic.200390009","article-title":"Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers","volume":"3","author":"Miller","year":"2003","journal-title":"Proteomics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.molonc.2016.09.007","article-title":"A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray","volume":"10","author":"Pin","year":"2016","journal-title":"Mol Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"B68","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"B72","doi-asserted-by":"publisher","first-page":"l1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/j.1464-410X.2008.08327.x","article-title":"Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer","volume":"103","author":"Aragon-Ching","year":"2009","journal-title":"BJU Int"},{"key":"B75","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/annonc\/mdp323","article-title":"Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy","volume":"21","author":"Sonpavde","year":"2010","journal-title":"Ann Oncol"},{"key":"B76","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2005","article-title":"NCCN task force report: mTOR inhibition in solid tumors","volume":"6","author":"Figlin","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"B77","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/pros.20752","article-title":"RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid","volume":"68","author":"Morgan","year":"2008","journal-title":"Prostate"},{"key":"B78","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.clgc.2014.08.007","article-title":"A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer","volume":"13","author":"Courtney","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1634\/theoncologist.2009-0009","article-title":"The role of Src in solid tumors","volume":"14","author":"Wheeler","year":"2009","journal-title":"Oncologist"},{"key":"B81","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"B82","doi-asserted-by":"publisher","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","article-title":"Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells","volume":"65","author":"Nam","year":"2005","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1158\/0008-5472.CAN-07-2997","article-title":"Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model","volume":"68","author":"Park","year":"2008","journal-title":"Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/CAD.0b013e328361feb0","article-title":"A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy","volume":"24","author":"Twardowski","year":"2013","journal-title":"Anticancer Drugs"},{"key":"B85","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.4161\/cbt.8.22.9770","article-title":"Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation","volume":"8","author":"Araujo","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"B87","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/CAD.0b013e328325a867","article-title":"A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study","volume":"20","author":"Lara","year":"2009","journal-title":"Anticancer Drugs"},{"key":"B88","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/pros.23119","article-title":"Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: a University of Chicago Phase 2 Consortium and DOD\/PCF Prostate Cancer Clinical Trials Consortium Study","volume":"76","author":"Posadas","year":"2016","journal-title":"Prostate"},{"key":"B89","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","article-title":"A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer","volume":"71","author":"Antonarakis","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/annonc\/mdp111","article-title":"Phase II study of sunitinib in men with advanced prostate cancer","volume":"20","author":"Dror Michaelson","year":"2009","journal-title":"Ann Oncol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","article-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1","volume":"34","author":"Smith","year":"2016","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.urolonc.2010.09.018","article-title":"A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer","volume":"31","author":"Whang","year":"2013","journal-title":"Urol Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1464-410X.2006.06396.x","article-title":"A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy","volume":"98","author":"Lin","year":"2006","journal-title":"BJU Int"},{"key":"B94","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1200\/JCO.2005.02.129","article-title":"Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group","volume":"23","author":"Canil","year":"2005","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2407-7-142","article-title":"A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer","volume":"7","author":"Gross","year":"2007","journal-title":"BMC Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(13)70479-0","article-title":"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial","volume":"14","author":"Araujo","year":"2013","journal-title":"Lancet Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/j.1464-410X.2012.11667.x","article-title":"Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer","volume":"111","author":"Dahut","year":"2013","journal-title":"BJU International"},{"key":"B98","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","article-title":"Integrated proteogenomic characterization of human high-grade serous ovarian cancer","volume":"166","author":"Zhang","year":"2016","journal-title":"Cell"},{"key":"B100","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1158\/1078-0432.CCR-0754-03","article-title":"Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation","volume":"10","author":"Matei","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/IJWH.S52379","article-title":"New perspectives on targeted therapy in ovarian cancer","volume":"7","author":"Coward","year":"2015","journal-title":"Int J Womens Health"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ygyno.2012.07.126","article-title":"A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma","volume":"128","author":"Campos","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1097\/JTO.0b013e31822e7256","article-title":"Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma","volume":"6","author":"Tsao","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jprot.2013.07.023","article-title":"Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors","volume":"91","author":"Schweppe","year":"2013","journal-title":"J Proteomics"},{"key":"B108","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature18003","article-title":"Proteogenomics connects somatic mutations to signalling in breast cancer","volume":"534","author":"Mertins","year":"2016","journal-title":"Nature"},{"key":"B109","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature13438","article-title":"Proteogenomic characterization of human colon and rectal cancer","volume":"513","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"B110","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nprot.2010.196","article-title":"Absolute quantification of protein and post-translational modification abundance with stable isotope-labeled synthetic peptides","volume":"6","author":"Kettenbach","year":"2011","journal-title":"Nat Protoc"},{"key":"B111","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nmeth.2309","article-title":"Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry","volume":"10","author":"Gillette","year":"2013","journal-title":"Nat Methods"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1074\/mcp.O115.050351","article-title":"Peptide immunoaffinity enrichment and targeted mass spectrometry enables multiplex, quantitative pharmacodynamic studies of phospho-signaling","volume":"14","author":"Whiteaker","year":"2015","journal-title":"Mol Cell Proteomics"},{"key":"B113","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/mas.20219","article-title":"Techniques for phosphopeptide enrichment prior to analysis by mass spectrometry","volume":"29","author":"Dunn","year":"2010","journal-title":"Mass Spectrom Rev"},{"key":"B114","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nbt.3327","article-title":"High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics","volume":"33","author":"Humphrey","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1002\/pmic.201500161","article-title":"Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry","volume":"15","author":"Shao","year":"2015","journal-title":"Proteomics"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/7651_2017_87","article-title":"High-throughput proteomic analysis of fresh-frozen biopsy tissue samples using pressure cycling technology coupled with SWATH mass spectrometry","author":"Zhu","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.molcel.2016.12.005","article-title":"A strategy to combine sample multiplexing with targeted proteomics assays for high-throughput protein signature characterization","volume":"65","author":"Erickson","year":"2017","journal-title":"Mol Cell"},{"key":"B118","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40169-017-0138-5","article-title":"Integrating phosphoproteomics into the clinical management of prostate cancer","volume":"6","author":"Cheng","year":"2017","journal-title":"Clin Transl Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1002\/elps.200700933","article-title":"Fasting status as a consideration for human serum collection and preparation prior to depletion and analysis","volume":"29","author":"Byrne","year":"2008","journal-title":"Electrophoresis"},{"key":"B120","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.bbrc.2006.12.111","article-title":"Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine","volume":"353","author":"M\u2019Koma","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B121","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1021\/pr8003216","article-title":"Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers","volume":"7","author":"Sardana","year":"2008","journal-title":"J Proteome Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijms.2010.10.003","article-title":"Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids","volume":"304","author":"Sharma","year":"2011","journal-title":"Int J Mass Spectrom"},{"key":"B123","doi-asserted-by":"publisher","first-page":"18925","DOI":"10.3390\/ijms140918925","article-title":"The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients","volume":"14","author":"Elshimali","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B124","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.eururo.2016.11.024","article-title":"Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer","volume":"71","author":"Scher","year":"2017","journal-title":"Eur Urol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","article-title":"Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer","volume":"13","author":"Danila","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2015.07.014","article-title":"Exosomes: emerging biomarkers and targets for ovarian cancer","volume":"367","author":"Tang","year":"2015","journal-title":"Cancer Lett"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9010008","article-title":"Exosomes in cancer diagnostics","volume":"9","author":"Soung","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e82589","DOI":"10.1371\/journal.pone.0082589","article-title":"Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer","volume":"8","author":"Duijvesz","year":"2013","journal-title":"PLoS One"},{"key":"B130","doi-asserted-by":"publisher","first-page":"30357","DOI":"10.18632\/oncotarget.4851","article-title":"Identification of prostate cancer biomarkers in urinary exosomes","volume":"6","author":"\u00d8verbye","year":"2015","journal-title":"Oncotarget"},{"key":"B131","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1074\/mcp.M117.068577","article-title":"Database-augmented mass spectrometry analysis of exosomes identifies claudin 3 as a putative prostate cancer biomarker","volume":"16","author":"Worst","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"B132","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature01254","article-title":"Computational systems biology","volume":"420","author":"Kitano","year":"2002","journal-title":"Nature"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2018.00028\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T02:11:58Z","timestamp":1603851118000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2018.00028\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":132,"alternative-id":["10.3389\/fonc.2018.00028"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00028","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,16]]},"article-number":"28"}}